Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
BACKGROUND
Patients with rheumatoid arthritis (RA) are at increased risk of malignant lymphomas, and maybe also of leukaemia and multiple myeloma. The effect of tumour necrosis factor (TNF) antagonists on lymphoma risk and characteristics is unclear.


OBJECTIVE
To assess expected rates and relative risks of haematopoietic malignancies, especially those associated with TNF antagonists, in large population based cohorts of patients with RA.


METHODS
A population based cohort study was performed of patients with RA (one prevalent cohort (n = 53,067), one incident cohort (n = 3703), and one TNF antagonist treated cohort 1999 through 2003 (n = 4160)), who were linked with the Swedish Cancer Register. Additionally, the lymphoma specimens for the 12 lymphomas occurring in patients with RA exposed to TNF antagonists in Sweden 1999 through 2004 were reviewed.


RESULTS
Study of almost 500 observed haematopoietic malignancies showed that prevalent and incident patients with RA were at increased risk of lymphoma (SIR = 1.9 and 2.0, respectively) and leukaemia (SIR = 2.1 and 2.2, respectively) but not of myeloma. Patients with RA treated with TNF antagonists had a tripled lymphoma risk (SIR = 2.9) compared with the general population. After adjustment for sex, age, and disease duration, the lymphoma risk after exposure to TNF antagonists was no higher than in the other RA cohorts. Lymphomas associated with TNF antagonists had characteristics similar to those of other RA lymphomas.


CONCLUSIONS
Overall, patients with RA are at equally increased risks for lymphomas and leukaemias. Patients with RA treated with TNF antagonists did not have higher lymphoma risks than other patients with RA. Prolonged observation is needed to determine the long term effects of TNF antagonists on lymphoma risk.
Askling
J
J
Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden. johan.askling@medks.ki.se
Fored
C M
CM
Baecklund
E
E
Brandt
L
L
Backlin
C
C
Ekbom
A
A
Sundström
C
C
Bertilsson
L
L
Cöster
L
L
Geborek
P
P
Jacobsson
L T
LT
Lindblad
S
S
Lysholm
J
J
Rantapää-Dahlqvist
S
S
Saxne
T
T
Klareskog
L
L
Feltelius
N
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000453:epidemiology; D004812:Epidemiologic Methods; D005260:Female; D019337:Hematologic Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D007938:Leukemia / Q000139:chemically induced / Q000453:epidemiology; D008223:Lymphoma / Q000139:chemically induced / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D013548:Sweden / Q000453:epidemiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha